Literature DB >> 8944364

Immune response to Clostridium difficile infection.

C P Kelly1.   

Abstract

Clostridium difficile produces two toxins (A and B) which cause antibiotic-associated diarrhoea and pseudomembranous colitis. One of the most puzzling aspects of C. difficile infection is the wide spectrum of clinical presentation which ranges from asymptomatic carriage to fulminant, life-threatening colitis. This review examines the hypothesis that immune responses to C. difficile underlie these dramatic variations in disease presentation and course. Animals can be protected from C. difficile colitis by passive or active immunization against toxins A and B. Human antibody responses to these toxins are evident in approximately 60% of the general population. A number of clinical studies indicate that antitoxin responses in both serum and intestinal secretions may be protective whereas an inadequate immune response predisposes to severe or recurrent C. difficile diarrhoea. Thus there is now considerable interest in developing methods for passive and active immunization to combat this prevalent nosocomial intestinal pathogen.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8944364     DOI: 10.1097/00042737-199611000-00004

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  20 in total

Review 1.  Review of medical and surgical management of Clostridium difficile infection.

Authors:  B Faris; A Blackmore; N Haboubi
Journal:  Tech Coloproctol       Date:  2010-05-08       Impact factor: 3.781

Review 2.  Refractory Clostridium difficile-associated diarrhea.

Authors:  Shilpa Grover; Matthew J Hamilton; David L Carr-Locke
Journal:  MedGenMed       Date:  2007-05-29

3.  Bovine immunoglobulin concentrate-clostridium difficile retains C difficile toxin neutralising activity after passage through the human stomach and small intestine.

Authors:  M Warny; A Fatimi; E F Bostwick; D C Laine; F Lebel; J T LaMont; C Pothoulakis; C P Kelly
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

4.  Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications.

Authors:  Ramsey M Dallal; Brian G Harbrecht; Arthur J Boujoukas; Carl A Sirio; Linda M Farkas; Kenneth K Lee; Richard L Simmons
Journal:  Ann Surg       Date:  2002-03       Impact factor: 12.969

Review 5.  Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Authors:  Ardeshir Rineh; Michael J Kelso; Fatma Vatansever; George P Tegos; Michael R Hamblin
Journal:  Expert Rev Anti Infect Ther       Date:  2014-01       Impact factor: 5.091

6.  Transcutaneous immunization with Clostridium difficile toxoid A induces systemic and mucosal immune responses and toxin A-neutralizing antibodies in mice.

Authors:  Chandrabali Ghose; Anuj Kalsy; Alaullah Sheikh; Julianne Rollenhagen; Manohar John; John Young; Sean M Rollins; Firdausi Qadri; Stephen B Calderwood; Ciaran P Kelly; Edward T Ryan
Journal:  Infect Immun       Date:  2007-03-19       Impact factor: 3.441

7.  Intravenous immunoglobulin therapy for severe Clostridium difficile colitis.

Authors:  J Salcedo; S Keates; C Pothoulakis; M Warny; I Castagliuolo; J T LaMont; C P Kelly
Journal:  Gut       Date:  1997-09       Impact factor: 23.059

8.  Saccharomyces boulardii stimulates intestinal immunoglobulin A immune response to Clostridium difficile toxin A in mice.

Authors:  A Qamar; S Aboudola; M Warny; P Michetti; C Pothoulakis; J T LaMont; C P Kelly
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

9.  Treatment of Clostridium difficile Infection.

Authors:  John R. Stroehlein
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06

10.  Open-label, dose escalation phase I study in healthy volunteers to evaluate the safety and pharmacokinetics of a human monoclonal antibody to Clostridium difficile toxin A.

Authors:  Claribel P Taylor; Sanjeev Tummala; Deborah Molrine; Lisa Davidson; Richard J Farrell; Anthony Lembo; Patricia L Hibberd; Israel Lowy; Ciaran P Kelly
Journal:  Vaccine       Date:  2008-05-07       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.